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Figure 1. Forest plot of the hazard ratios for mortality associated with LIC>7 mg/gdw (Panel A) and ferritin>1000 ng/ml (Panel B).
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in the subgroup of patients with MDS or acute leukemia, as
did the absence of signiﬁcant association between OS and
LIC. There was also no signiﬁcant association between LIC
and OS among patients conditioned with a myeloablative
regimen. In analyses of NRM, there was a trend towards
increased NRM for LIC>7 mg/gdw (HR¼1.74, p¼0.09) and for
ferritin>1000 ng/ml (HR¼1.55, p¼0.14) but neither reached
statistical signiﬁcance. There was no signiﬁcant association
between elevated ferritin or LIC and NRM among patients
who received a myeloablative conditioning or among acute
leukemia/MDS patients. In conclusion, despite the conﬁrmed
adverse prognosis conferred by pre-HSCT hyperferritinemia,
our meta-analysis suggests that iron overload, as assessed by
MRI-determined liver iron content, is not a signiﬁcant factor
for OS or NRM. This raises the possibility that the deleterious
prognostic impact of ferritin on survival is related to other
issues such as inﬂammatory status, infection, or disease
characteristics. These results may inform future research on
the use of chelation therapy in HSCT.9
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Mycophenolate mofetil (MMF) is commonly used in reduced
intensity conditioning (RIC) allogeneic hematopoietic cell
transplantation (HCT) for graft-versus-host disease (GVHD)
prophylaxis and to facilitate engraftment. We previously
reported that higher level of mycophenolic acid can be ach-
ieved with MMF administered at 3 g/day MMF as compared
to 2g/day dose in patients (pts) with RIC transplantation.
Thus, we retrospectively compared clinical outcomes of pts
with hematological malignancies undergoing myloablative
(MA, n¼147) and RIC (n¼265) double umbilical cord blood
HCT (dUCBT) who received MMF 2g (n¼139) vs. 3g (n¼273)
daily. In multiple regression analysis after adjusting for
conditioning regimen (NMA RR 1.98, 95%CI, 1.59-2.47;
p<0.01), HLA disparity (HLA-match 6/6 RR 1.84, 95%CI, 1.21-
2.82; p<0.01; 5/6 RR 1.05; 95%CI 0.83-1.33, p¼0.67; ref 4/6)
and infused CD34 dose ( 3.5 x107/kg RR 1.63, 95%CI 1.27-
2.09, p<0.01; ref <3.5x107/kg), MMF dosing was not an in-
dependent predictor of neutrophil engraftment (MMF 3 g RR
0.83, 95% CI 0.66-1.05; p¼0.12; ref MMF 2g). However, after
adjustment for gender (female RR 0.72, 95%CI 0.54-0.94;
p¼0.02) and conditioning (NMA RR 0.72, 95%CI 0.55-0.95;
p¼0.02), MMF 3 g/day led to 42% reduction in grade II-IV
acute GVHD rate (RR¼0.58, 95%CI 0.45-0.76; p<0.01). Higher
MMF dosewas not protective for chronic GVHD (RR 0.73, 95%
CI 0.48-1.11; p¼0.15). The effect of MMF dosing on the risk of
infections was evaluated by cumulative density function that
accounts for multiple infectious events in an individual pt.
When we studied the effect of MMF dose on frequency of
bacterial, fungal and viral infections using speciﬁc post-
transplant time intervals (Figure), MMF 2g/day resulted in
signiﬁcantly higher density of bacterial infections (8.37 vs.
6.07 per 1000 pt days, p<0.01) and total infectious events
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between post-transplant days 46-180, the period when pts
with GVHD are on systemic immunosuppression. The most
frequent bacterial infections were staphylococcus (n¼ 129),
enterococcus (n¼56), clostridium difﬁcile (n¼42), pseudo-
monas (n¼18), mycobacterium (n¼9), and others (n¼54). In
contrast, MMF dose had no impact on speciﬁc infection types
at post-transplant days 0-45 and days 181-365. Additionally,
MMF dose was not an independent predictor of treatment
related mortality at 6 months (RR 1.38, 95%CI 0.91-2.10,
p¼0.13), or 2-year post-transplant disease relapse (RR 1.08,
95%CI 0.74-1.59, p¼0.69), disease free survival (RR 1.17, 95%CI
0.89-1.53, p¼0.26), or overall survival (RR 1.27, 95%CI 0.94-
1.72, p¼0.12). Infection related mortality rate was similar
between two groups (14% MMF 2g vs. 16% MMF 3g, p¼0.55).
Our data indicates that MMF 3g/day dosing reduces the risk
of acute GVHD without increasing the risk of infectious
complications and it should be used for GVHD prophylaxis
following dUCBT.10
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Introduction: Multiple approaches have been made to
minimize graft versus host disease (GvHD) after allogeneicFigure 1a. Overall survival (OS) rates and Figure 1b. Relapse-free survival (RFS) rates
who were in remission (dark line) at the time of their transplant.hematopoietic cell transplantation (allo-HCT) without
compromising graft versus leukemia (GvL) effect. Use of high
dose cyclophosphamide in the early post-transplant period
(PT-Cy) has signiﬁcantly improved the outcomes of allo-HCT
and encouraging results using this regimen have been
recently reported in both haploidentical and non-hap-
loidentical transplant setting (Bashey et al JCO, 2013, Fuchs et
al, Blood, 2010). However, so far the use of peripheral blood
stem cells (PBSC) with non-myeloablative (NMA) conditioning
PT-Cy has not been reported in literature.
Patients and methods: A total of 21 patients (median age
45 (22-74) years, 12 males and 9 females) between July 2009
and June 2013 underwent allo-HCT on this regimen. The
NMA conditioning consisted of Fludarabine (30mg/m2/day
on days -6 to -2), Cyclophosphamide (14.5 mg/kg/day on D -6
and -5) and TBI (200cGy on D -1) and Cyclophosphamide
(50mg/kg-bw on D +3 and D +4). PBSC was used a graft
source with a median CD34+ count of 5 x 106/kg-bw and
CD3+ T cell dose of 19.7 x 107/kg-bw. GvHD prophylaxis
included MMF plus Tacrolimus. Median follow-up for the
patients was 235 (17-1174) days. Diagnosis of the patients
included AML (n¼14), ALL (n¼2), CML (n¼1), NHL (n¼2), CLL
(n¼1) and Aplastic anemia (n¼1). 10 out of 21 patients un-
derwent transplant in active disease and 4 of these patients
had prior history of allo-HCT.
Results: 19 patients (95%) engrafted with median neutrophil
engraftment on day 15 (12-28) days and median platelet
engraftment on day 16 (11-40) days. None of these patients
had secondary graft failure. 1 year over all survival rates (OS)
of 57% were encouraging. The 1-year OS for those underwent
transplant with active disease and in remissionwere 63% and
56% respectively (Figure 1a). 1-year relapse free survival
(RFS) was 56% for those who underwent transplant in
remission and 41% in those who underwent transplant in
active disease (Figure 1b). 100 day and 1-year NRM rates
were 9.5% and 14% respectively. Cumulative incidence of
aGvHD at 2 months and 90 days was 38% and 47% respec-
tively (grade III-IV in 4 patients). Cumulative incidence of
cGvHD at 1 and 2 years were both at 12% (extensive in 1
patient). CMV reactivation occurred in 14 patients (66%)
without the development of CMV disease.
Conclusions: Herewe report for the ﬁrst time the results of a
novel regimen combining NMA conditioning with T-cell
replete G-CSF mobilized PBSC for allo-HCT with high dosein patients after allo-HCT, patients with active disease (dashed line), patients
